A High-Risk Period for Cerebrovascular Events Exists After Transcatheter Aortic Valve Implantation

被引:142
作者
Tay, Edgar L. W. [1 ]
Gurvitch, Ronen [1 ]
Wijesinghe, Namal [1 ]
Nielispach, Fabian [1 ]
Wood, David [1 ]
Cheung, Anson [1 ]
Ye, Jian [1 ]
Lichtenstein, Samuel V. [1 ]
Carere, Ronald [1 ]
Thompson, Christopher [1 ]
Webb, John G. [1 ]
机构
[1] Univ British Columbia, St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
关键词
antiplatelet therapy; antithrombotic therapy; percutaneous aortic valve replacement; stroke; transient ischemic attack(s); SHORT-TERM; REPLACEMENT; STROKE; WARFARIN;
D O I
10.1016/j.jcin.2011.08.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study assesses if there exists a high-risk period for cerebrovascular events (CeV) after transcatheter aortic valve implantation (TAVI). Background Even though acute strokes after TAVI have been described, it is uncertain if stroke rates continue to remain high in the early months after TAVI. Furthermore, the optimal dose and duration of thromboprophylaxis is unclear. Methods Patients who underwent TAVI were evaluated at baseline, at discharge, at 1 and 6 months, and yearly. Risk factors for CeV events, procedural details, and antithrombotic therapy were recorded. Outcomes assessed were CeV events and death. The timing of such events, predictors, and impact on survival were analyzed. Results A total of 253 patients were assessed. Median age was 85 years. The median Society of Thoracic Surgeons score was 8.1% (interquartile range [IQR]: 5.5% to 12.0%). Risk factors included smoking (47%), hypertension (70%), dyslipidemia (66%), and diabetes mellitus (25%). Twenty-three percent had known cerebrovascular disease and 39% had atrial fibrillation. Median follow-up was 455 days (IQR: 160 to 912 days) at which time 23 patients experienced a CeV event. The incidence was highest in the first 24 h but remained high for 2 months. In-hospital mortality rate after a CeV event was 21%, A prior history of CeV disease was an independent predictor of an event (hazard ratio: 4.23, 95% Cl: 1.60 to 11.11, p = 0.004). Conclusions The incidence of CeV events is highest within 24 h of TAVI, but this risk may remain elevated for up to 2 months. A prior history of cerebrovascular disease is an independent predictor. This may have implications for patient selection and antithrombotic strategies. (J Am Coll Cardiol Intv 2011;4:1290-7) (C) 2011 by the American College of Cardiology Foundation
引用
收藏
页码:1290 / 1297
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 1991, Circulation, V84, P2383, DOI [10.1161/01.CIR.84.6.2383, DOI 10.1161/01.CIR.84.6.2383]
[2]   The potential of myocardial perfusion scintigraphy for risk stratification of asymptomatic patients with type 2 diabetes [J].
Bax, Jeroen J. ;
Bonow, Robert O. ;
Tschoepe, Diethelm ;
Inzucchi, Silvio E. ;
Barrett, Eugene .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (04) :754-760
[3]   Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin [J].
Becker, RC ;
Eisenberg, P ;
Turpie, AGG .
AMERICAN HEART JOURNAL, 2001, 141 (06) :1025-1037
[4]   Risk and Fate of Cerebral Embolism After Transfemoral Aortic Valve Implantation A Prospective Pilot Study With Diffusion-Weighted Magnetic Resonance Imaging [J].
Ghanem, Alexander ;
Mueller, Andreas ;
Naehle, Claas P. ;
Kocurek, Justine ;
Werner, Nikos ;
Hammerstingl, Christoph ;
Schild, Hans H. ;
Schwab, Joerg O. ;
Mellert, Fritz ;
Fimmers, Rolf ;
Nickenig, Georg ;
Thomas, Daniel .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (14) :1427-1432
[5]   Comparing warfarin with aspirin after biological aortic valve replacement - A prospective study [J].
Gherli, T ;
Colli, A ;
Fragnito, C ;
Nicolini, F ;
Borrello, B ;
Saccani, S ;
D'Amico, R ;
Beghi, C .
CIRCULATION, 2004, 110 (05) :496-500
[6]   Short-term effects of transcatheter aortic valve implantation on neurohormonal activation, quality of life and 6-minute walk test in severe and symptomatic aortic stenosis [J].
Gotzmann, Michael ;
Hehen, Tobias ;
Germing, Alfried ;
Lindstaedt, Michael ;
Yazar, Aydan ;
Laczkovics, Axel ;
Mumme, Achim ;
Muegge, Andreas ;
Bojara, Waldemar .
HEART, 2010, 96 (14) :1102-1106
[7]  
Grewe PH, 2000, Z KARDIOL, V89, P21, DOI 10.1007/s003920050004
[8]   PLATELET CONSUMPTION BY ARTERIAL PROSTHESES - EFFECTS OF ENDOTHELIALIZATION AND PHARMACOLOGIC INHIBITION OF PLATELET-FUNCTION [J].
HARKER, LA ;
SLICHTER, SJ ;
SAUVAGE, LR .
ANNALS OF SURGERY, 1977, 186 (05) :594-601
[9]   HIGH-RISK OF THROMBOEMBOLI EARLY AFTER BIOPROSTHETIC CARDIAC-VALVE REPLACEMENT [J].
HERAS, M ;
CHESEBRO, JH ;
FUSTER, V ;
PENNY, WJ ;
GRILL, DE ;
BAILEY, KR ;
DANIELSON, GK ;
ORSZULAK, TA ;
PLUTH, JR ;
PUGA, FJ ;
SCHAFF, HV ;
LARSONKELLER, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (05) :1111-1119
[10]   Results of Transfemoral or Transapical Aortic Valve Implantation Following a Uniform Assessment in High-Risk Patients With Aortic Stenosis [J].
Himbert, Dominique ;
Descoutures, Fleur ;
Al-Attar, Nawwar ;
Iung, Bernard ;
Ducrocq, Gregory ;
Detaint, Delphine ;
Brochet, Eric ;
Messika-Zeitoun, David ;
Francis, Fady ;
Ibrahim, Hassan ;
Nataf, Patrick ;
Vahanian, Alec .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (04) :303-311